Join Growin Stock Community!

微邦3184.TW Overview

TW StockBiotech. & Medical
(No presentation for 3184)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

微邦（3184）Overall Performance

微邦（3184）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

微邦（3184） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

微邦（3184）Key Information

微邦（3184）Profile

MicroBase Technology Corp. provides drug delivery systems to patients and healthcare professionals in Taiwan. It develops non-silicon-based MEMS by using LIGA technology that could be applied in the manufacture and development of miniaturized devices and micron-scale parts. The company also offers Pocket Air, an inhalation devices for the treatment of respiratory diseases; and PharMatrix, a micro-needles products for women to use at home. MicroBase Technology Corp. was founded in 1997 and is based in Taoyuan City, Taiwan.

微邦（3184）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
1.36
PE Ratio (TTM)
9.07
Forward PE
-
PS Ratio (TTM)
1.89
PB Ratio
1.20
Price-to-FCF
17.34
METRIC
VALUE
vs. INDUSTRY
Gross Margin
52.55%
Net Margin
20.85%
Revenue Growth (YoY)
4.28%
Profit Growth (YoY)
52.91%
3-Year Revenue Growth
-18.45%
3-Year Profit Growth
-20.23%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
1.36
PE Ratio (TTM)
9.07
Forward PE
-
PS Ratio (TTM)
1.89
PB Ratio
1.20
Price-to-FCF
17.34
Gross Margin
52.55%
Net Margin
20.85%
Revenue Growth (YoY)
4.28%
Profit Growth (YoY)
52.91%
3-Year Revenue Growth
-18.45%
3-Year Profit Growth
-20.23%
default symbol

3184

微邦

12.35D

-5.67%

(-0.06)

  • When is 3184's latest earnings report released?

    The most recent financial report for 微邦 (3184) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 3184's short-term business performance and financial health. For the latest updates on 3184's earnings releases, visit this page regularly.

  • Where does 3184 fall in the P/E River chart?

    According to historical valuation range analysis, 微邦 (3184)'s current price-to-earnings (P/E) ratio is 19.32, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • How much cash does 3184 have?

    At the end of the period, 微邦 (3184) held Total Cash and Cash Equivalents of 197.1M, accounting for 0.25 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 3184 go with three margins increasing?

    In the latest report, 微邦 (3184) achieved the “three margins increasing” benchmark, with a gross margin of 58.74%%, operating margin of 29.96%%, and net margin of 17.03%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 3184's profit trajectory and future growth potential.